

December 6, 2023

Charter of the Friends of the Personalized Medicine Coalition

Whereas.... We believe that a revolution in health care is underway, known as personalized medicine, catalyzed by rapidly emerging information from life sciences research and the availability of sophisticated information technologies;

Whereas.... We are witnessing the initial clinical benefits of personalized medicine strategies and products, in the form of a new generation of molecular diagnostics and targeted therapeutics that can improve efficacy and reduce adverse side effects;

Whereas.... We wish to accelerate the adoption of personalized medicine to improve individual patient outcomes as well as the overall effectiveness of the health care system;

Whereas.... We view the mission of the PMC – to educate federal and state policymakers and private sector healthcare leaders about personalized medicine, helping them understand the science, the issues and what is needed for the positive evolution of personalized medicine – as critically important;

Whereas.... The PMC has demonstrated its unique role in the field by encompassing all sectors of the biomedical enterprise within its membership, and effectively framing the debate around the key obstacles to adoption of personalized medicine;

Whereas.... We believe that, in addition to the membership role played by each of our organizations in the PMC, there is an opportunity for individual leadership and commitment to advance the goals of the PMC;

Hereby Be It Resolved that.... We as individuals establish and support the Friends of the Personalized Medicine Coalition, and invite our colleagues and peers to join us.

Friends of the Personalized Medicine Coalition (2010 – 2023)

- Bonnie J. Addario
- Kathleen Behrens
- Brook Byers
- Neil de Crescenzo
- Michael Goldberg
- Marcia Kean
- Raju Kucherlapati
- Mark Levin
- Kimberly Popovits
- Ralph Snyderman
- Anne Wojcicki

BOARD OF DIRECTORS

President

Edward Abrahams, Ph.D.

Chair

Lincoln D. Nadauld, M.D., Ph.D.
Culmination Bio

Vice Chair

Lauren Silvis, J.D.
Tempus

Treasurer

Peter Maag, Ph.D.
Kyverna Therapeutics

Secretary

Michael S. Sherman, M.D., M.B.A., M.S.
RA Capital Management

Gabriele Allegrì, M.B.A.
Johnson and Johnson Innovative
Medicine

Antonio L. Andreu, M.D., Ph.D.
European Infrastructure for Translational
Research (EATRIS)

Randy Burkholder
PhRMA

Dawn Cardeiro, M.S.
Point32Health

Brian Caveney, M.D.
Labcorp

William S. Dalton, Ph.D., M.D.
Aster Insights

Stephen L. Eck, M.D., Ph.D.
MacroGenics

Helmy Eltoukhy, Ph.D.
Guardant Health

Lori Frank, Ph.D.
New York Academy of Medicine

Sarah Hersey
Bristol Myers Squibb

Steffan Ho, M.D., Ph.D.
Pfizer

Richard Knight
American Association of Kidney Patients

Mia Levy, M.D., Ph.D.
Foundation Medicine

James W. Lillard, Ph.D.
Morehouse School of Medicine

Howard McLeod, Pharm.D.
Clarified Precision Medicine

J. Brian Munroe
Bausch Health Companies

Elizabeth O'Day, Ph.D.
Olaris

Joshua Ofman, M.D.
Grail

Prasanth Reddy, M.D.

Apostolia Tsimberidou, M.D., Ph.D.
MD Anderson Cancer Center

Michael J. Vasconcelles, M.D.
ImmunoGen

Jay G. Wohlgenuth, M.D.
Trusted Health Advisors